Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2022

Pharma News, 2022

FDA Grants Priority Review for Enfortumab Vedotin-ejfv, Pembrolizumab for Treatment of Urothelial Cancer
FDA Grants Priority Review for Enfortumab Vedotin-ejfv, Pembrolizumab for Treatment of Urothelial Cancer

The FDA granted Priority Review to both applications and set a Prescription Drug User Fee Act goal date for each application of April 21, 2023.

Pfizer files blockbuster hope etrasimod for ulcerative colitis
Pfizer files blockbuster hope etrasimod for ulcerative colitis
Regulators in the US and EU have started a review of Pfizer’s S1P receptor modulator etrasimod for people living with moderately-to-severely active ulcerative colitis (UC), with decisions expecte...
FDA Approves Preservative-Free Latanoprost Drug for Elevated Intraocular Pressure
FDA Approves Preservative-Free Latanoprost Drug for Elevated Intraocular Pressure
The FDA has approved Laboratoires Théa subsidiary Thea Pharma’s Iyuzeh (latanoprost ophthalmic solution) 0.005 percent to reduce elevated intraocular pressure in individuals with open-angle glau...
A way to make asthma drugs last longer
A way to make asthma drugs last longer
For many, inhalers are a sort of miracle drug. From gasping for air one minute, to breathing normally the next, patients can experience significant relief after one or two puffs.  ...
FDA Pauses IND Submission for Duchenne Therapy ENTR-601-44
FDA Pauses IND Submission for Duchenne Therapy ENTR-601-44

In preclinical studies, ENTR-601-44 has demonstrated a robust ability to skip exon 44 in the muscles of nonhuman primates and full-length human DMD mice.

AbbVie’s Vraylar Gets Expanded Approval for Major Depressive Disorder
AbbVie’s Vraylar Gets Expanded Approval for Major Depressive Disorder
The FDA has expanded its approval for AbbVie’s blockbuster antipsychotic drug Vraylar (cariprazine), this time as an adjunctive treatment along with antidepressants to treat adults with major dep...
EU regulators issue guidance on decentralised trials
EU regulators issue guidance on decentralised trials
The EU has published new recommendations aiming to encourage the use of decentralised clinical trials (DCTs) – and to make sure patients who participate in them have their wellbeing safeguarded. ...
FDA Expands Approval for Cytalux Imaging for Lung Cancer Detection
FDA Expands Approval for Cytalux Imaging for Lung Cancer Detection
The FDA has approved a new indication for pafolacianine (Cytalux) to aid surgeons in detecting lung cancer lesions in adult patients with known or suspected lung cancer. ...
FDA Approves First Gene Therapy for Specific Form of Bladder Cancer
FDA Approves First Gene Therapy for Specific Form of Bladder Cancer
The FDA has approved Ferring’s gene therapy Adstiladrin to treat adults with high-risk Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer — the first gene therapy approv...
Vanda Loses Hetlioz Patent Case
Vanda Loses Hetlioz Patent Case
Vanda Pharmaceuticals has vowed to appeal a federal judge’s dismissal of several patent infringement claims aimed at Teva Pharmaceuticals and Apotex over their generic forms of its sleep disorder...
Neurophth Receives IND Clearance from FDA for AAV-ND1 Gene Therapy of LHON
Neurophth Receives IND Clearance from FDA for AAV-ND1 Gene Therapy of LHON
Neurophth Therapeutics, Inc. today announced receiving the U.S. Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application on the in-vivo gene replacement therap...
Kintara’s VAL-083 Gets Orphan Drug Status for Rare Childhood Cancer
Kintara’s VAL-083 Gets Orphan Drug Status for Rare Childhood Cancer
The FDA has granted Orphan Drug status to Kintara Therapeutics’ VAL-083 candidate for the treatment of diffuse intrinsic pontine glioma, a rare, very aggressive and hard to treat childhood brain...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand